Bitopertin’s Schizophrenia Failure Stirs Doubt About Roche’s CNS Plans
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche’s bitopertin fails in the first two of six Phase III schizophrenia trials to report, raising questions about prospects for more diversity outside the company’s core strength in oncology.